We assessed the cardiovascular safety of long-term direct-acting oral anticoagulant (DOAC)
treatment. A search of the medical literature was performed from inception until May 31 …

Despite contemporary management, patients with coronary artery disease (CAD) remain at
high risk for thrombotic events. Several randomized controlled trials have evaluated the use …

In the pivotal randomized controlled trials (RCTs) for patients with atrial fibrillation, direct oral
anticoagulants (DOACs) had similar or even superior efficacy and safety compared with …

Aims There are concerns regarding increased risk of acute coronary syndrome with
dabigatran. We aimed to assess whether alternative treatment options such as rivaroxaban …

Background A meta-analysis was performed to evaluate the risk of major bleeding with the
use of New Oral Anticoagulants (NOACs). Methods Randomized controlled trials (RCTs) …

The relative cardiovascular (CV) safety of oral anticoagulants continues to be debated, and
in particular concerns for risk of myocardial infarction (MI) have been raised. We analyzed …

Until recently, vitamin K antagonists (VKAs) were the only available oral anticoagulants
evaluated for long-term treatment of patients with coronary heart disease (CHD), particularly …

Background This study was designed to compare efficacy and safety among novel oral
anticoagulants (NOACs), which have not been directly compared in randomized control …

What is known and objective Anticoagulation is important in the management of
cardiovascular disorders; however, traditional anticoagulants such as heparins and vitamin …

Objective To investigate the associations between direct oral anticoagulants (DOACs) and
risks of bleeding, ischaemic stroke, venous thromboembolism, and all cause mortality …